what is SMART?
SMART is a program of the OVCARE consortium designed to advance the treatment of patients with the less common forms of cancer. SMART is co-led by Drs. Jessica McAlpine and Anna Tinker of the B.C. Cancer Agency and is supported by a multi-disciplinary team of clinical investigators and research scientists in OVCARE directed by Dr. David Huntsman.
To learn more about OVCARE, click on the logo below.
The SMART Cancer Project was designed to help study rare cancers. To study a cancer well, researchers need to treat many people with that cancer in a standard and uniform fashion so that they can get a good measure of the benefits of treatment. Rare cancers are harder to study this way. It can take a long time to find patients with rare cancer types, and often the research has to include many collaborators and even patients from different countries...
Shared Access Medicine: an Approach to Rare Tumours (SMART) is a registry for rare histo-types and molecular subtypes of different types of cancer. Many rare tumours have no more than one “standard” historical therapeutic approach. Patients who remain well enough for further treatment are typically treated empirically with additional agents or participate in Phase I trials available at their centres...
SMART currently has one study open for registration. As new projects on other tumour types are developed, this section will be updated.
HER2+ Mucinous Ovarian Cancers
If you are sure you have a mucinous ovarian cancer, and you need treatment for your cancer at this time or you have been told that treatment might be needed in the future, please ask your doctor to look at the information on this website and discuss whether this information relates to you.